Product information and disease description Place of product in therapy Disease description Epidemiology

Incidence of Wet age-related macular degeneration

10 evidence topics · 5 sources

Summary: incidence

In a Bayesian meta-analysis of cohort studies in populations of European ancestry, the annual incidence of neovascular AMD in White US adults aged 50 years or older was 1.8 per 1,000, and the incidence of any late AMD was 3.5 per 1,000 (about 293,000 new cases per year). A US cost-benefit analysis estimated 168,400 new-onset neovascular AMD cases in 2018. In the Beaver Dam Eye Study (3,917 participants), the 15-year cumulative incidence of exudative AMD was 4.4% in participants aged 75 years or older at baseline and 0.4% in those aged 43 to 54 years.

Annual incidence in White US adults: meta-analysis

“Annual incidence (estimated from prevalence) of late AMD in American whites was 3.5 per 1000 aged ≥50 years (95% credible interval 2.5, 4.7 per 1000), equivalent to 293 000 new cases in American whites per year (95% credible interval 207 000, 400 000). Incidence rates approximately quadrupled per decade in age. Annual incidence GA rates were 1.9 per 1000 aged ≥50 years, NVAMD rates were 1.8 per 1000.” (opens the source at this quote in a new tab)

New-onset neovascular AMD cases in the United States, 2018

“168,400 estimated 2018 U.S. patients with new-onset NVAMD.” (opens the source at this quote in a new tab)

Beaver Dam Eye Study: 15-year cumulative incidence

“The 15-year cumulative incidence was 14.3% for early AMD (the presence of either soft indistinct drusen or the presence of pigmentary abnormalities together with any type of drusen) and 3.1% for late AMD (presence of exudative AMD or geographic atrophy).” (opens the source at this quote in a new tab)
“Individuals > or = 75 years of age at baseline had significantly (P<0.01) higher 15-year incidences of the following characteristics than people 43 to 54 years of age: larger drusen (125 mum in diameter, 24.1% vs 10.6%), soft indistinct drusen (18.7% vs 6.5%), retinal pigmentary abnormalities (20.2% vs 3.7%), exudative macular degeneration (4.4% vs 0.4%), and pure geographic atrophy (3.2% vs 0%).” (opens the source at this quote in a new tab)

Neovascular AMD in the fellow eye: untreated cohorts

“Neovascular AMD developed in the fellow eye in 12.2% of patients by 12 months and in 26.8% by 4 years.” (opens the source at this quote in a new tab)

Progression to advanced AMD in the fellow eye

“In the AREDS, the risk of progression for patients with advanced AMD in one eye to an advanced stage in the fellow eye ranged from 35% to 50% at 5 years, depending largely on the phenotype in the better eye.” (opens the source at this quote in a new tab)

Annual incidence and number of new neovascular AMD cases in White US adults

“The corresponding rates for GA and NVAMD are 1.9 per 1000 (95% credible interval 1.3, 2.8) and 1.8 per 1000 (95% credible interval 1.2, 2.5), respectively (Table 3).” (opens the source at this quote in a new tab)
“This corresponds to approximately 293 000 new cases of late AMD each year (95% credible interval 207 000, 400 000), and 160 000 (95% credible interval 107 000, 234 000) and 148 000 (95% credible interval 103 000, 207 000) for GA and NVAMD, respectively.” (opens the source at this quote in a new tab)
“Although our overall estimates of NVAMD incidence are high (owing to the inclusion of those at older ages, especially in women), this does not reflect the number in need of treatment.” (opens the source at this quote in a new tab)
“Of note, the inclusion of older ages in our estimates may include a large number who are unwilling or too frail to undergo treatment.” (opens the source at this quote in a new tab)

Neovascular AMD incidence by age: 65 years or older and 80 years or older

“In those aged 65 years and older the annual incidence rate for late AMD is 7.8 per 1000 (95% credible interval 5.5, 10.6), 4.3 per 1000 for GA (95% credible interval 2.9, 6.2), and 3.9 per 1000 for NVAMD (95% credible interval 2.7, 5.5).” (opens the source at this quote in a new tab)
“In those aged 80 years and older the annual incidence rates per 1000 are 19.4 (95% credible interval 13.8, 26.2), 10.9 (95% credible interval 7.2, 16.1), and 9.9 (95% credible interval 6.8, 14.0), respectively.” (opens the source at this quote in a new tab)
“A meta-analysis of incidence studies showed that the incidence rate for late AMD triples per decade increase in age (rate ratio 2.9; 95% credible interval 2.6, 3.2, Table 2).” (opens the source at this quote in a new tab)
“Although late AMD incidence increases log-linearly with age, the absolute number of incident cases of late AMD decreases beyond the age of about 85 years because of increased mortality.” (opens the source at this quote in a new tab)

Neovascular AMD incidence by sex

“Incidence rates for late AMD were 38% higher in women than in men (rate ratio 1.4, 95% credible interval 1.1, 1.8).” (opens the source at this quote in a new tab)
“For all age groups (except the youngest), women have a slightly higher annual incidence rate of late AMD (4 per 1000, 95% credible interval 2.3, 6.6) than men (2.4 per 1000, 95% credible interval 1.4, 4.2; Table 3).” (opens the source at this quote in a new tab)
“In those aged 65 years and older the incidence rates of NVAMD within each 5-year age group are higher in women than in men.” (opens the source at this quote in a new tab)
“Under 70 years of age the number of incident cases is similar in men and women.” (opens the source at this quote in a new tab)

Fellow-eye incidence: effect of outlier studies

“These cumulative incidence rates were influenced by significant heterogeneity in the studies caused by outliers.” (opens the source at this quote in a new tab)
“If outliers were not included in the analysis, the 12-month incidence rate changed considerably, from 12.2% to 8.1% (95% CI, 4.9-11.9).” (opens the source at this quote in a new tab)
“Excluding these outliers from the analysis reduced the 12-month incidence rate changes considerably, from 12.2% to 8.1% (95% CI, 4.9%-11.9%), which is lower than the approximately 12% per year rate reported by other single studies in the literature.” (opens the source at this quote in a new tab)